Akt1 Polyclonal Antibody, 50ul[BT-AP00348] Drug Development and Evaluation It is responsible for decreased

It is responsible for decreased drug accumulation in multidrug-resistant cells and often mediates the development of resistance to anticancer drugs

where it has been shown to enhance the secretory activity of this gland

TAL1 and TCF3

Selenocysteine lyase (SCLY

CENPB (MIM 117140)

Akt1 Polyclonal Antibody, 50ul[BT-AP00348] Drug Development and Evaluation It is responsible for decreasedThe serine threonine protein kinase encoded by the AKT1 gene is catalytically inactive in serum starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1. It was shown that the activation occurs through phosphatidylinositol 3 kinase. In the developing nervous system AKT is a